Search hospitals > Michigan > Flint

Genesee Cancer and Blood Disease Treatment Center

Claim this profile
Flint, Michigan 48503
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Adenocarcinoma
178 reported clinical trials
7 medical researchers
Photo of Genesee Cancer and Blood Disease Treatment Center in FlintPhoto of Genesee Cancer and Blood Disease Treatment Center in Flint

Summary

Genesee Cancer and Blood Disease Treatment Center is a medical facility located in Flint, Michigan. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Genesee Cancer and Blood Disease Treatment Center is involved with conducting 178 clinical trials across 348 conditions. There are 7 research doctors associated with this hospital, such as Tareq Al Baghdadi, Christopher M. Reynolds, MD, Philip J. Stella, and Elie G. Dib.

Area of expertise

1Cancer
Global Leader
Genesee Cancer and Blood Disease Treatment Center has run 86 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Lung Cancer
Global Leader
Genesee Cancer and Blood Disease Treatment Center has run 32 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II

Top PIs

Clinical Trials running at Genesee Cancer and Blood Disease Treatment Center

Breast Cancer
Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Esophageal Cancer
Bladder Cancer
Esophageal Adenocarcinoma
Multiple Myeloma
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Support Program

for Breast Cancer

This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Image of trial facility.

Carvedilol

for Preventing Heart Problems in HER2 Positive Breast Cancer

This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Genesee Cancer and Blood Disease Treatment Center?
Genesee Cancer and Blood Disease Treatment Center is a medical facility located in Flint, Michigan. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Genesee Cancer and Blood Disease Treatment Center is involved with conducting 178 clinical trials across 348 conditions. There are 7 research doctors associated with this hospital, such as Tareq Al Baghdadi, Christopher M. Reynolds, MD, Philip J. Stella, and Elie G. Dib.